Pharmaceutical Company Akorn Agrees To Pay $7.9 Million For Allegedly Causing Medicare To Pay For Invalid Prescription Drugs
Pharmaceutical company Akorn Operating Company LLC (Akorn) has agreed to pay $7.9 million to resolve allegations that it caused the submission of false claims to Medicare Part D, in violation of the False Claims Act, for three generic drugs that were no longer eligible for Medicare coverage.
Action Details
- Date:September 15, 2022
- Agency:U.S. Department of Justice
-
Enforcement Types:
- Criminal and Civil Actions